Stem definition | Drug id | CAS RN |
---|---|---|
antivirals phosphonic acid derivatives | 2592 | 147127-20-6 |
None
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.83 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.93 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 5, 2009 | FDA | HETERO DRUGS LTD | |
March 25, 2004 | PMDA | Japan Tobacco Inc. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Maternal exposure during pregnancy | 198.52 | 30.95 | 110 | 2191 | 159668 | 50443155 |
Drug resistance | 138.18 | 30.95 | 46 | 2255 | 18943 | 50583880 |
Rebound effect | 130.31 | 30.95 | 30 | 2271 | 3159 | 50599664 |
Virologic failure | 110.10 | 30.95 | 23 | 2278 | 1541 | 50601282 |
Drug interaction | 102.09 | 30.95 | 79 | 2222 | 199542 | 50403281 |
Foetal exposure during pregnancy | 100.39 | 30.95 | 40 | 2261 | 27319 | 50575504 |
Immune reconstitution inflammatory syndrome | 95.07 | 30.95 | 26 | 2275 | 5490 | 50597333 |
Fanconi syndrome acquired | 91.21 | 30.95 | 18 | 2283 | 905 | 50601918 |
Viral mutation identified | 86.55 | 30.95 | 19 | 2282 | 1610 | 50601213 |
Exposure during pregnancy | 82.34 | 30.95 | 57 | 2244 | 120958 | 50481865 |
Hepatitis B | 72.29 | 30.95 | 19 | 2282 | 3447 | 50599376 |
Premature delivery | 54.84 | 30.95 | 25 | 2276 | 23638 | 50579185 |
Pathogen resistance | 54.47 | 30.95 | 17 | 2284 | 5672 | 50597151 |
Birth mark | 49.23 | 30.95 | 8 | 2293 | 130 | 50602693 |
Congenital umbilical hernia | 49.08 | 30.95 | 9 | 2292 | 304 | 50602519 |
Fanconi syndrome | 48.05 | 30.95 | 11 | 2290 | 1125 | 50601698 |
Abortion spontaneous | 46.70 | 30.95 | 27 | 2274 | 41745 | 50561078 |
Blood HIV RNA increased | 44.03 | 30.95 | 9 | 2292 | 540 | 50602283 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 42.21 | 30.95 | 8 | 2293 | 324 | 50602499 |
Autoimmune hepatitis | 42.11 | 30.95 | 15 | 2286 | 7504 | 50595319 |
Renal tubular dysfunction | 41.28 | 30.95 | 8 | 2293 | 365 | 50602458 |
Hypophosphataemic osteomalacia | 40.64 | 30.95 | 7 | 2294 | 164 | 50602659 |
Glycosuria | 37.85 | 30.95 | 9 | 2292 | 1085 | 50601738 |
Ergot poisoning | 37.06 | 30.95 | 6 | 2295 | 95 | 50602728 |
Glucocorticoids increased | 35.46 | 30.95 | 6 | 2295 | 126 | 50602697 |
Stillbirth | 33.80 | 30.95 | 12 | 2289 | 5940 | 50596883 |
Treatment noncompliance | 32.39 | 30.95 | 19 | 2282 | 30131 | 50572692 |
Abortion induced | 31.93 | 30.95 | 13 | 2288 | 9331 | 50593492 |
Hereditary optic atrophy | 30.99 | 30.95 | 4 | 2297 | 10 | 50602813 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Immune reconstitution inflammatory syndrome | 227.71 | 22.88 | 73 | 4536 | 7729 | 29562189 |
Psychiatric decompensation | 150.66 | 22.88 | 37 | 4572 | 1467 | 29568451 |
Retinal toxicity | 149.00 | 22.88 | 29 | 4580 | 375 | 29569543 |
Depression suicidal | 145.25 | 22.88 | 35 | 4574 | 1280 | 29568638 |
Mitochondrial toxicity | 137.96 | 22.88 | 38 | 4571 | 2373 | 29567545 |
Tearfulness | 137.66 | 22.88 | 35 | 4574 | 1601 | 29568317 |
Lipodystrophy acquired | 137.39 | 22.88 | 40 | 4569 | 3054 | 29566864 |
Progressive external ophthalmoplegia | 134.96 | 22.88 | 33 | 4576 | 1284 | 29568634 |
Drug interaction | 123.22 | 22.88 | 152 | 4457 | 197233 | 29372685 |
Acquired gene mutation | 121.21 | 22.88 | 30 | 4579 | 1228 | 29568690 |
Hepatitis B | 118.63 | 22.88 | 41 | 4568 | 5456 | 29564462 |
Fanconi syndrome acquired | 100.62 | 22.88 | 28 | 4581 | 1814 | 29568104 |
Eyelid ptosis | 90.33 | 22.88 | 33 | 4576 | 5153 | 29564765 |
Foetal exposure during pregnancy | 86.60 | 22.88 | 58 | 4551 | 33809 | 29536109 |
Depressive symptom | 84.24 | 22.88 | 24 | 4585 | 1693 | 29568225 |
Drug resistance | 83.26 | 22.88 | 48 | 4561 | 21492 | 29548426 |
Paranoia | 79.15 | 22.88 | 36 | 4573 | 9841 | 29560077 |
Psychomotor skills impaired | 77.96 | 22.88 | 25 | 4584 | 2636 | 29567282 |
Pathogen resistance | 76.01 | 22.88 | 33 | 4576 | 8083 | 29561835 |
Psychotic disorder | 72.44 | 22.88 | 43 | 4566 | 20311 | 29549607 |
Hepatic failure | 71.16 | 22.88 | 50 | 4559 | 31462 | 29538456 |
Diplopia | 62.78 | 22.88 | 34 | 4575 | 13484 | 29556434 |
Gene mutation | 62.28 | 22.88 | 17 | 4592 | 1024 | 29568894 |
Ophthalmoplegia | 50.07 | 22.88 | 16 | 4593 | 1666 | 29568252 |
Hepatitis B reactivation | 46.92 | 22.88 | 18 | 4591 | 3211 | 29566707 |
Suicidal ideation | 45.56 | 22.88 | 40 | 4569 | 34676 | 29535242 |
Congenital umbilical hernia | 43.95 | 22.88 | 10 | 4599 | 283 | 29569635 |
Birth mark | 43.54 | 22.88 | 9 | 4600 | 160 | 29569758 |
Drug-induced liver injury | 43.45 | 22.88 | 32 | 4577 | 21623 | 29548295 |
Adrenal suppression | 42.86 | 22.88 | 11 | 4598 | 521 | 29569397 |
Night blindness | 41.14 | 22.88 | 9 | 4600 | 212 | 29569706 |
Psychomotor retardation | 37.63 | 22.88 | 15 | 4594 | 2961 | 29566957 |
Superior mesenteric artery syndrome | 37.51 | 22.88 | 7 | 4602 | 71 | 29569847 |
Nephropathy toxic | 36.36 | 22.88 | 22 | 4587 | 10734 | 29559184 |
BRASH syndrome | 32.62 | 22.88 | 7 | 4602 | 150 | 29569768 |
Fanconi syndrome | 30.93 | 22.88 | 11 | 4598 | 1587 | 29568331 |
Mitochondrial myopathy | 30.80 | 22.88 | 7 | 4602 | 197 | 29569721 |
Hepatocellular carcinoma | 30.72 | 22.88 | 17 | 4592 | 7021 | 29562897 |
Anxiety | 29.65 | 22.88 | 50 | 4559 | 85315 | 29484603 |
Osteomalacia | 28.84 | 22.88 | 9 | 4600 | 867 | 29569051 |
Renal tubular dysfunction | 25.89 | 22.88 | 7 | 4602 | 406 | 29569512 |
Portal hypertension | 25.70 | 22.88 | 12 | 4597 | 3474 | 29566444 |
Brachydactyly | 25.57 | 22.88 | 6 | 4603 | 195 | 29569723 |
Osteoporotic fracture | 23.74 | 22.88 | 8 | 4601 | 983 | 29568935 |
Hepatic fibrosis | 23.37 | 22.88 | 11 | 4598 | 3241 | 29566677 |
Depression | 23.33 | 22.88 | 45 | 4564 | 85102 | 29484816 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Immune reconstitution inflammatory syndrome | 340.42 | 20.91 | 100 | 6352 | 12370 | 64479910 |
Hepatitis B | 202.02 | 20.91 | 60 | 6392 | 7685 | 64484595 |
Drug interaction | 188.81 | 20.91 | 205 | 6247 | 361878 | 64130402 |
Drug resistance | 158.52 | 20.91 | 75 | 6377 | 35027 | 64457253 |
Progressive external ophthalmoplegia | 149.24 | 20.91 | 33 | 6419 | 1294 | 64490986 |
Retinal toxicity | 149.17 | 20.91 | 33 | 6419 | 1297 | 64490983 |
Psychiatric decompensation | 148.79 | 20.91 | 37 | 6415 | 2426 | 64489854 |
Mitochondrial toxicity | 145.33 | 20.91 | 37 | 6415 | 2669 | 64489611 |
Fanconi syndrome acquired | 144.40 | 20.91 | 36 | 6416 | 2385 | 64489895 |
Depression suicidal | 138.64 | 20.91 | 35 | 6417 | 2440 | 64489840 |
Acquired gene mutation | 136.00 | 20.91 | 33 | 6419 | 1953 | 64490327 |
Pathogen resistance | 135.70 | 20.91 | 50 | 6402 | 12493 | 64479787 |
Lipodystrophy acquired | 135.29 | 20.91 | 38 | 6414 | 3989 | 64488291 |
Maternal exposure during pregnancy | 119.35 | 20.91 | 89 | 6363 | 95795 | 64396485 |
Tearfulness | 116.61 | 20.91 | 35 | 6417 | 4638 | 64487642 |
Rebound effect | 102.18 | 20.91 | 32 | 6420 | 4885 | 64487395 |
Viral mutation identified | 87.55 | 20.91 | 26 | 6426 | 3320 | 64488960 |
Eyelid ptosis | 81.48 | 20.91 | 32 | 6420 | 9493 | 64482787 |
Psychomotor skills impaired | 79.79 | 20.91 | 25 | 6427 | 3820 | 64488460 |
Paranoia | 77.02 | 20.91 | 36 | 6416 | 16316 | 64475964 |
Fanconi syndrome | 76.77 | 20.91 | 22 | 6430 | 2479 | 64489801 |
Psychotic disorder | 76.63 | 20.91 | 46 | 6406 | 34532 | 64457748 |
Depressive symptom | 75.95 | 20.91 | 25 | 6427 | 4471 | 64487809 |
Gene mutation | 71.53 | 20.91 | 20 | 6432 | 2062 | 64490218 |
Hepatitis B reactivation | 69.97 | 20.91 | 24 | 6428 | 4865 | 64487415 |
Hepatic failure | 65.69 | 20.91 | 50 | 6402 | 55344 | 64436936 |
Virologic failure | 61.48 | 20.91 | 20 | 6432 | 3446 | 64488834 |
Nephropathy toxic | 57.03 | 20.91 | 30 | 6422 | 17484 | 64474796 |
CSF HIV escape syndrome | 53.11 | 20.91 | 11 | 6441 | 314 | 64491966 |
Diplopia | 52.63 | 20.91 | 33 | 6419 | 26732 | 64465548 |
Drug-induced liver injury | 52.10 | 20.91 | 41 | 6411 | 47602 | 64444678 |
Adrenal suppression | 46.74 | 20.91 | 13 | 6439 | 1314 | 64490966 |
Ophthalmoplegia | 45.53 | 20.91 | 15 | 6437 | 2687 | 64489593 |
Night blindness | 43.98 | 20.91 | 10 | 6442 | 445 | 64491835 |
Glycosuria | 41.01 | 20.91 | 13 | 6439 | 2061 | 64490219 |
Renal tubular dysfunction | 39.69 | 20.91 | 10 | 6442 | 690 | 64491590 |
Psychomotor retardation | 39.53 | 20.91 | 16 | 6436 | 5127 | 64487153 |
Hypophosphataemia | 39.00 | 20.91 | 22 | 6430 | 14698 | 64477582 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 38.71 | 20.91 | 10 | 6442 | 763 | 64491517 |
Suicidal ideation | 38.48 | 20.91 | 40 | 6412 | 66502 | 64425778 |
Blood HIV RNA increased | 36.52 | 20.91 | 11 | 6441 | 1473 | 64490807 |
Superior mesenteric artery syndrome | 35.20 | 20.91 | 7 | 6445 | 162 | 64492118 |
Hepatocellular carcinoma | 34.98 | 20.91 | 17 | 6435 | 8386 | 64483894 |
Exposure during pregnancy | 33.40 | 20.91 | 40 | 6412 | 77635 | 64414645 |
Osteomalacia | 32.90 | 20.91 | 10 | 6442 | 1381 | 64490899 |
Hepatic encephalopathy | 31.74 | 20.91 | 22 | 6430 | 21044 | 64471236 |
Mitochondrial myopathy | 31.46 | 20.91 | 7 | 6445 | 282 | 64491998 |
Foetal exposure during pregnancy | 31.25 | 20.91 | 13 | 6439 | 4463 | 64487817 |
Hypophosphataemic osteomalacia | 31.13 | 20.91 | 7 | 6445 | 296 | 64491984 |
Hereditary optic atrophy | 31.05 | 20.91 | 5 | 6447 | 32 | 64492248 |
Glucocorticoids increased | 30.73 | 20.91 | 6 | 6446 | 126 | 64492154 |
Ergot poisoning | 30.29 | 20.91 | 6 | 6446 | 136 | 64492144 |
Portal hypertension | 30.23 | 20.91 | 14 | 6438 | 6205 | 64486075 |
BRASH syndrome | 29.61 | 20.91 | 7 | 6445 | 370 | 64491910 |
Hepatic cirrhosis | 29.53 | 20.91 | 23 | 6429 | 26275 | 64466005 |
Renal impairment | 26.47 | 20.91 | 48 | 6404 | 134969 | 64357311 |
Renal tubular necrosis | 26.28 | 20.91 | 20 | 6432 | 22090 | 64470190 |
Meningitis cryptococcal | 25.34 | 20.91 | 10 | 6442 | 2999 | 64489281 |
Treatment noncompliance | 24.87 | 20.91 | 26 | 6426 | 43456 | 64448824 |
Premature delivery | 24.74 | 20.91 | 18 | 6434 | 18571 | 64473709 |
Autoimmune hepatitis | 23.85 | 20.91 | 14 | 6438 | 10070 | 64482210 |
Unmasking of previously unidentified disease | 23.23 | 20.91 | 8 | 6444 | 1639 | 64490641 |
HIV infection | 22.97 | 20.91 | 7 | 6445 | 975 | 64491305 |
Cerebral toxoplasmosis | 22.42 | 20.91 | 8 | 6444 | 1818 | 64490462 |
Hepatic fibrosis | 22.41 | 20.91 | 11 | 6441 | 5541 | 64486739 |
Malaise | 22.40 | 20.91 | 6 | 6446 | 396241 | 64096039 |
Abortion spontaneous | 21.96 | 20.91 | 19 | 6433 | 25124 | 64467156 |
Cushingoid | 21.87 | 20.91 | 12 | 6440 | 7591 | 64484689 |
Oligohydramnios | 21.56 | 20.91 | 9 | 6443 | 3115 | 64489165 |
Acute hepatic failure | 21.34 | 20.91 | 19 | 6433 | 26093 | 64466187 |
Abortion induced | 20.95 | 20.91 | 11 | 6441 | 6377 | 64485903 |
Vascular stent thrombosis | 20.92 | 20.91 | 9 | 6443 | 3355 | 64488925 |
None
Source | Code | Description |
---|---|---|
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
MeSH PA | D018894 | Reverse Transcriptase Inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:49103 | drug metabolites |
CHEBI has role | CHEBI:53756 | reverse transcriptase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic type B viral hepatitis | indication | 61977001 | |
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Coronavirus infection | off-label use | 186747009 | |
Prevention of HIV Infection after Exposure | off-label use | ||
Osteomalacia | contraindication | 4598005 | DOID:10573 |
Hypophosphatemia | contraindication | 4996001 | |
Suicidal thoughts | contraindication | 6471006 | |
Hypercholesterolemia | contraindication | 13644009 | |
Torsades de pointes | contraindication | 31722008 | |
Depressive disorder | contraindication | 35489007 | |
Fanconi syndrome | contraindication | 40488004 | DOID:1062 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Aggressive behavior | contraindication | 61372001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Prolonged QT interval | contraindication | 111975006 | |
Chronic hepatitis C | contraindication | 128302006 | |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Paranoid disorder | contraindication | 191667009 | |
Steatosis of liver | contraindication | 197321007 | |
Mania | contraindication | 231494001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pathological fracture | contraindication | 268029009 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Severe depression | contraindication | 310497006 | |
Osteopenia | contraindication | 312894000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Congenital long QT syndrome | contraindication | 442917000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 0.23 | acidic |
pKa2 | 4.92 | acidic |
pKa3 | 4.28 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Reverse transcriptase/RNaseH | Enzyme | IC50 | 6.42 | CHEMBL | |||||
Reverse transcriptase | Enzyme | IC50 | 6.42 | CHEMBL | |||||
Capsid protein | Unclassified | EC50 | 6.62 | CHEMBL |
ID | Source |
---|---|
4021279 | VUID |
N0000148716 | NUI |
D06074 | KEGG_DRUG |
4021279 | VANDF |
C0384228 | UMLSCUI |
CHEBI:63625 | CHEBI |
TFO | PDB_CHEM_ID |
CHEMBL483 | ChEMBL_ID |
CHEMBL3989702 | ChEMBL_ID |
CHEMBL1486 | ChEMBL_ID |
DB14126 | DRUGBANK_ID |
D000068698 | MESH_DESCRIPTOR_UI |
464205 | PUBCHEM_CID |
10948 | IUPHAR_LIGAND_ID |
99YXE507IL | UNII |
117466 | RXNORM |
d04774 | MMSL |
009357 | NDDF |
395264002 | SNOMEDCT_US |
422091007 | SNOMEDCT_US |
206184-49-8 | SECONDARY_CAS_RN |
None